Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TEVA
TEVA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TEVA News
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
Jun 12 2026
Fool
Biotech Sector Sees Surge in FDA and Global Approvals
Jun 12 2026
NASDAQ.COM
Teva Completes Acquisition of Emalex Biosciences for $700 Million
Jun 11 2026
NASDAQ.COM
Teva Acquires Emalex Biosciences to Enhance Pipeline for Tourette Syndrome
Jun 10 2026
Newsfilter
Alvotech's AVT16 Biosimilar Application Accepted by FDA
Jun 08 2026
seekingalpha
Teva Reports New Efficacy Data for Huntington's Disease Treatments
Jun 08 2026
NASDAQ.COM
Alvotech's AVT16 BLA Accepted by FDA for Review
Jun 08 2026
Globenewswire
Survey Reveals Daily Impact of Huntington's Disease Chorea on Patients and Caregivers
Jun 05 2026
Newsfilter
Teva Launches Eylea Biosimilar Ahzantive
Jun 04 2026
Yahoo Finance
Teva Launches AHZANTIVE Biosimilar in Europe
Jun 04 2026
Newsfilter
Alvotech Resubmits Biologics License Applications for Biosimilars
Jun 04 2026
NASDAQ.COM
Alvotech Resubmits Biologics License Applications for Biosimilars
Jun 04 2026
Globenewswire
UroGen Pharma Settles Patent Dispute with Teva Pharmaceuticals
Jun 02 2026
seekingalpha
Teva CEO to Participate in Goldman Sachs Healthcare Conference
Jun 01 2026
Newsfilter
Teva Pharmaceutical's Strong Comeback
Jun 01 2026
Fool
Teva Pharmaceutical's Transformation Fuels Stock Rebound
Jun 01 2026
NASDAQ.COM
Show More News
